Skip to content

US · ALMR · BIOTECHNOLOGY

Alamar Biosciences, Inc. (ALMR) intrinsic value and stock valuation

$26.48as of 2026-11-21 · Mkt cap 265.78M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alamar Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values ALMR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ALMR’s statements →

Alamar Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Fremont, CA 94538 alamarbio.com

How the business is doing

Fiscal 2025–2025, USD

Revenue
$74.2M
20252025
Net income
-$-29.82M
20252025
Free cash flow
-$-59.99M
20252025
Total equity
-$-158.95M
20252025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2025–2025, USD
2025
Revenue$74.2M
Operating income-$-31.33M
Net income-$-29.82M
EPSd-$-448.29K
Operating cash flow-$-53.61M
Capital expenditure-$-6.38M
Free cash flow-$-59.99M
Total assets$140M
Total debt$41.5M
Net debt$11.5M
Total equity-$-158.95M
Cash and short-term investments$30M
Income statement
2025
Revenue$74.2M
Cost of revenue$32.5M
Gross profit$41.7M
Research and development expenses$37.5M
Selling, general and administrative expenses$35.6M
Other expenses$0.00
Operating expenses$73M
Cost and expenses$105.6M
Interest income$2.16M
Interest expense$400K
Depreciation and amortization$3.86M
Ebitda-$-24.89M
Operating income-$-31.33M
Total other income/expenses, net$2.18M
Income before tax-$-29.15M
Income tax expense$670K
Net income-$-29.82M
Weighted average shares outstanding$66.5M
Weighted average diluted shares outstanding$66.5M
Balance sheet
2025
Cash and short-term investments$30M
Net receivables$12.8M
Inventory$38.5M
Total current assets$94.7M
Property, plant and equipment, net$36.6M
Goodwill and intangible assets$1.99M
Long-term investments$0.00
Total non-current assets$45.3M
Total assets$140M
Accounts payable$5.87M
Short-term debt$2.1M
Deferred revenue$470K
Total current liabilities$23.7M
Long-term debt$39.4M
Deferred revenue, non-current$0.00
Total non-current liabilities$275.2M
Capital lease obligations$31.7M
Total liabilities$299M
Common stock$0.00
Retained earnings-$-168.78M
Accumulated other comprehensive income (loss)-$-70K
Total equity-$-158.95M
Total investments$0.00
Total debt$41.5M
Net debt$11.5M
Cash flow statement
2025
Net income-$-29.82M
Depreciation and amortization$3.86M
Stock-based compensation$2.87M
Change in working capital-$-32.57M
Accounts receivable-$-5.5M
Inventory-$-23.78M
Accounts payable-$-570K
Net cash provided by operating activities-$-53.61M
Investments in property, plant and equipment-$-5.37M
Acquisitions, net$0.00
Net cash used for investing activities$46.2M
Common stock issued$1.49M
Common stock repurchased$0.00
Dividends paid$0.00
Net cash used for financing activities$10.8M
Net change in cash$3.23M
Cash at end of period$34.9M
Operating cash flow-$-53.61M
Capital expenditure-$-6.38M
Free cash flow-$-59.99M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alamar Biosciences, Inc.

        Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.

        CEO
        Yuling Luo
        Employees
        222
        Beta
        -6.18

        Explore

        Frequently asked questions

        What is the intrinsic value of Alamar Biosciences, Inc. (ALMR)?

        InvestorsCraft does not currently publish an intrinsic value for ALMR. How the IC value is calculated.

        Is ALMR undervalued?

        InvestorsCraft does not publish an undervaluation signal for ALMR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.